Fintel reports that on June 3, 2025, Oppenheimer initiated coverage of Axsome Therapeutics (NasdaqGM:AXSM) with a Outperform ...

In a report dated May 30, Morgan Stanley analyst Vikram Purohit reaffirmed his Buy rating on Axsome Therapeutics Inc. (NASDAQ ...

NEW YORK, May 29, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders ...

Greetings, and welcome to the Axsome Therapeutics first-quarter 2025 conference call and webcast. (Operator Instructions) As a reminder, this conference is being recorded. It's now my pleasure to ...

Axsome Therapeutics, Inc. (NASDAQ: AXSM) Johnson Fistel, PLLP is investigating claims on behalf of Axsome Therapeutics, Inc. against certain of its officers and directors. If you are a current ...

Axsome Therapeutics, Inc. has a 12 month low of $64.11 and a 12 month high of $139.13. Axsome Therapeutics ( NASDAQ:AXSM – Get Free Report ) last issued its quarterly earnings results on Tuesday ...

Short interest in Axsome Therapeutics Inc (NASDAQ:AXSM) decreased during the last reporting period, falling from 4.20M to 3.89M. This put 9.53% of the company's publicly available shares short.

Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States. The company’s ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Dr. Roger A. Jeffs is a Chief Executive Officer & Director at Liquidia Corp., a Vice Chairman at Kriya Therapeutics, Inc., a Lead Independent Director at Axsome Therapeutics, Inc. and a Co-Owner ...

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio ...